Seneca Biopharma Inc (AKA: Neuralstem Inc) Profile last edited on: 3/8/2025
CAGE: 1WH52
UEI: RNZ2EFVDQDW3
Business Identifier: Applying stem cell research and technology in treatment of central nervous system diseases 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
20271 Goldenrod Lane Suite 2024
Germantown, MD 20876
Germantown, MD 20876
| (301) 366-4960 |
| info@senecabio.com |
| www.senecabio.com |
Location: Single
Congr. District: 06
County: Montgomery
Congr. District: 06
County: Montgomery
Public Profile
Seneca Biopharma, Inc., (NASDAQ: SNCA) is a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need. It will be a great help to athletes and sportspersons to treat their health issues instantly. The health of players is very important for bettors as it may affect the game. Punters may check the WM Sieger Sportwetten blog to find the betting providers without Oasis. Seneca is in the process of finding and acquiring new assets, promising sciences and technologies that will provide meaningful therapies for patients.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : SNCAIP Holdings
50-74Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2018 | 1 | DHA | $149,976 | |
| Project Title: Neural Stem Cell Therapy for Severe Traumatic Brain Injury | ||||
| 2018 | 2 | NIH | $997,069 | |
| Project Title: Development of NSI-189, a Novel Neurogenic Molecule, to Prevent and Treat Diabetic Neuropathy | ||||
| 2006 | 2 | NIH | $500,000 | |
| Project Title: Novel Neurogenic Agents as Depression Therapeutics | ||||
| 2003 | 1 | CBD | $69,861 | |
| Project Title: Identification of Compounds to Induce Suspended Animation or Hypometabolism | ||||
Key People / Management
Kenneth C Carter -- CEO & Exec. Chairman
I Richard Garr -- President and Founder
Thomas G Hazel -- Senior Vice President, Research
Karl K Johe -- Founder and Chief Scientific Officer
Kimberly Kasprowicz -- Senior Project Manager
David P Recker -- Chief Medical Officer
I Richard Garr -- President and Founder
Thomas G Hazel -- Senior Vice President, Research
Karl K Johe -- Founder and Chief Scientific Officer
Kimberly Kasprowicz -- Senior Project Manager
David P Recker -- Chief Medical Officer
